Dauntless,
You always seem to make things simple. So, let me try. While we have both agreed and disagreed in the past, I'd like you to first allow me to let the folks know that you are not a passive investor. In fact, let's be honest and disclose your affiliation with Zonagen. You were a consultant to the company. While your consulting relationship ended a few years ago, you still maintain your close relationship to Joe P as well as others at the company. Therefore, those who are don't know this information can place your posts in some context.
As for your interpretation of the lawsuit (which I too have read), it leaves much to be desired (read you colored the facts). The "fraud" that is being asserted by the former employee was due to the fact that officers at Zonagen knowlingly filed a patent for ImmuMax, a compound that is, essentially, Chitosan. Chitosan was patented years prior to the Zonagen filing. The filing of the patent without specific disclosure of the existing prior art for Chitosan is what Asensio considered "fraudulent." This may or may not be true, but it sure is a gray area and not a simple matter for any of us to decide, but it could be considered as "character" for the case in hand. Furthermore, why don't you tell us why Schering AG hasn't acted on its call option? I believe this call runs out at mid-year.
Again, while we have agreed and disagreed before on Zonagen, you should not feel like you have any advantage given your physical proximity to the boys at Zonagen.
Tokyo |
